ROC曲线对原发性胆汁性肝硬化患者预后诊断阈值的确定及意义

赵丹彤; 廖慧钰; 刘燕敏; 黄春洋; 张海萍; 孙丽梅; 马胤雪; 赵艳; 闫惠平

doi:10.3969/j.issn.1001-5256.2014.01.017

ROC曲线对原发性胆汁性肝硬化患者预后诊断阈值的确定及意义

DOI: 10.3969/j.issn.1001-5256.2014.01.017

1. 首都医科大学附属北京佑安医院自身免疫性肝病临床研究中心
2. 首都医科大学附属北京佑安医院肝病免疫科

基金项目:

首都卫生发展科研专项项目(首发2011-2018-05)；

详细信息

中图分类号: R575.22
计量
- 文章访问数: 3097
- HTML全文浏览量: 19
- PDF下载量: 633
- 被引次数: 1
出版历程
- 收稿日期: 2013-05-08
- 出版日期: 2014-01-20

ROC analysis of prognostic factors in Chinese patients with primary biliary cirrhosis

Clinical Research Center for Autoimmune Liver Disease, Beijing You'an Hospital, Capital Medical University

Research funding:

摘要

摘要:
目的采用受试者工作特征（ROC）曲线确定原发性胆汁性肝硬化（PBC）患者生存预后诊断阈值并评价其临床意义。方法以2001年10月至2009年9月北京佑安医院收治的155例确诊PBC患者为研究对象,进行随访,随访终点事件为死亡和（或）进行肝移植。对患者临床资料进行分析,符合正态分布的定量资料采用独立样本t检验,偏态分布的定量资料采用Wilcoxon秩和检验;计数资料采用χ2检验;偏态分布定量资料或分类变量资料采用Spearman秩相关分析法。采用ROC曲线确定预后诊断指标及阈值,采用Kaplan-Meier法进行组间生存率,评价临床意义。结果随访中位时间为50个月（6316个月）,36例患者出现终点事件（33例患者死亡,3例患者进行了肝移植）。年龄≥55岁、TBil>1.8 mg/dl、血清总IgG>17.2 g/L、Mayo评分（MRS）>6.11对肝硬化阶段PBC患者具有预后诊断价值;4项指标作联合分析,串联的特异度可达99.18%,灵敏度为5.56%,总符合率为79.23%;并联时,其灵敏度可达100%,特异度为24.51%,总符合率为40....
- 肝硬化,胆汁性 /
- ROC曲线 /
- 存活率分析 /
- 预后
Abstract:
Objective To investigate and assess prognostic factors for survival in patients with primary biliary cirrhosis ( PBC) by receiver operating characteristics ( ROC) curves and Kaplan- Meier methods. Methods A total of 155 patients were identified and followed. Terminal events were death and / or liver transplantation. The optimal thresholds for continuous variables were established by ROC curves and cumulative proportions of patients developing an event were estimated using the Kaplan- Meier method. Results During a median follow- up period of 50 months ( range: 6- 316) , 36 patients died or underwent liver transplantation. Age 55 years or older, Total Bilirubin ( TBil) > 1. 8mg / dl, serum IgG > 17. 2 g / L, and Mayo risk score ( MRS) > 6. 11 were associated with mortality. With four markers in series test, their sensitivity was 99. 18%, specificity was 5. 56%, the total coincidence rate was 79. 23%; With four markers in parallel test, their sensitivity was 100%, specificity was 24. 51%, the total coincidence rate was 40. 77%. Age 55 years or older ( P = 0. 001) , TBil > 1. 8mg / dl ( P = 0. 005) , serum IgG > 17. 2 g / L ( P = 0. 001) , and MRS > 6. 11 ( P < 0. 000 1) were significantly associated with mortality. Conclusion Age 55 years or older, TBil > 1. 8mg / dL, serum IgG > 17. 2 g / L, and MRS > 6. 11 might predict survival for PBC patients with liver cirrhosis.
- liver cirrhosis, biliary /
- ROC curve /
- survival analysis /
- prognosis

HTML全文

参考文献(17)

[1]European Association for the Study of the Liver.EASL clinical practice guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[2]JIN HH, DING XH.ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J].J Clin Hepatol, 2012, 28 (6) :456-458. (in Chinese) 金宏慧, 丁晓红.受试者工作特征曲线分析血小板计数与透明质酸对肝硬化的诊断价值[J].临床肝胆病杂志, 2012, 28 (6) :456-458.

[3]WU XQ, WAN H.Causes of failure and impact analysis of prognostic risk factors[J].J Clin Hepatol, 2013, 29 (4) :294-296. (in Chinese) 吴晓庆, 万红.肝衰竭预后的危险因素分析[J].临床肝胆病杂志, 2013, 29 (4) :294-296.

[4]DICKSON ER, GRAMBSCH PM, FLEMING TR, et al.Prognosis in primary biliary cirrhosis:model for decision making[J].Hepatology, 1989, 10 (1) :1-7.

[5] LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.

[6]WONG GL, HUI AY, WONG VW, et al.A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients[J].Am J Gastroenterol, 2005, 100 (10) :2205-2211.

[7]SU CW, HUNG HH, HUO TI, et al.Natural history and prognostic factors of primary biliary cirrhosis in Taiwan:a follow-up study up to 18 years[J].Liver Int, 2008, 28 (9) :1305-1313.

[8]WONG RK, LIM SG, WEE A, et al.Primary biliary cirrhosisin Singapore:evaluation of demography, prognostic factors and natural course in a multi-ethnic population[J].J Gastroenterol Hepatol, 2008, 23 (4) :599-605.

[9]PRINCE M, CHETWYND A, NEWMAN W, et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology, 2002, 123 (4) :1044-1051.

[10]PARS A, CABALLERíA L, RODS J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J].Gastroenterology, 2006, 130 (3) :715-720.

[11]PETERS MG, di BISCEGLIE AM, KOWDLEY KV, et al.Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States[J].Hepatology, 2007, 46 (3) :769-775.

[12]GERSHWIN ME, VIERLING JM, MANNS MP.Liver Immunology:principles and practice[M].NY:Humana Press, 2007:235-247.

[13]KLION FM, FABRY TL, PALMER M, et al.Prediction of survival of patients with primary biliary cirrhosis.Examination of the Mayo Clinic model on a group of patients with known endpoint[J].Gastroenterology, 1992, 102 (1) :310-313.

[14]KIM WR, WIESNER RH, THERNEAU TM, et al.Optimal timing of liver transplantation for primary biliary cirrhosis[J].Hepatology, 1998, 28 (1) :33-38.

[15]VELZQUEZ RF, RODRíGUEZ M, NAVASCUS CA, et al.Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J].Hepatology, 2003, 37 (3) :520-527.

[16]ZHAO DT, LIAO HY, LIU YM, et al.Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients[J].Dig Dis Sci, 2011, 56 (9) :2750-2757.

[17]LIU YM, LIAO HY, YAN HP.Diagnosis of autoimmune liver diseases[J].Beijing Med J, 2012, 34 (12) :1084-1086. (in Chinese) 刘燕敏, 廖慧钰, 闫惠平.自身免疫性肝病诊断思路[J].北京医学, 2012, 34 (12) :1084-1086.

施引文献